NIH NIDA Development of Medications to Prevent and Treat Substance Use Disorders (SUDs) and Overdose (UG3/UH3 - Clinical Trial Optional)

The National Institute on Drug Abuse (NIDA) seeks research for the discovery and development of medications to prevent and treat substance use disorders (SUDs) and overdose.

 The UG3/UH3 Phased Innovation Awards Cooperative Agreement funding mechanism involves 2 phases. The UG3 is to support a project with specific milestones to be accomplished by the end of the 2-year period. The UH3 is to provide funding for 3 years to a project that successfully completed the milestones set in the UG3. UG3 projects that have met their milestones will be administratively considered by NIDA and prioritized for transition to the UH3 phase. Investigators responding to this FOA must address both UG3 and UH3 phases.

Through this funding opportunity, NIDA seeks to fast-track the discovery and development of medications to prevent and treat SUDs and overdose and to advance them in the FDA's pathway.

Apply Now